spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  factor VIII 

 HSMN NewsFeed - 19 Jun 2024
European Commission grants Sobi(R) Marketing Authorisation for ALTUVOCT(TM) for treatment of haemophilia A
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 26 Apr 2024
Sobi(R) Receives Positive CHMP Opinion Recommending Approval of Efanesoctocog Alfa for Once-Weekly Treatment of Haemophilia A
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 10 Nov 2023
EU Approval of AAV5 DetectCDx(TM) Provides Access to Companion Diagnostic for Hemophilia A Gene Therapy
Diagnostics Regulatory
 HSMN NewsFeed - 24 Feb 2023
FDA approves once-weekly efanesoctocog alfa, a new class of high-sustained factor VIII therapy for haemophilia A: Swedish Orphan Biovitrum AB
Biopharmaceuticals FDA
 HSMN NewsFeed - 23 Nov 2022
BioMarin Announces Advancements in FDA Review of ROCTAVIAN(TM) (Valoctocogene Roxaparvovec) for Adults with Severe Hemophilia A
Biopharmaceuticals FDA
 HSMN NewsFeed - 24 Jun 2022
BioMarin Receives Positive CHMP Opinion in Europe for Valoctocogene Roxaparvovec Gene Therapy to Treat Adults with Severe Hemophilia A
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 8 Mar 2021
BioMarin Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Valoctocogene Roxaparvovec, Investigational Gene Therapy for Hemophilia A
Biopharmaceuticals FDA
 HSMN NewsFeed - 6 Apr 2020
HEMA Biologics(TM) Announces FDA Approval of SEVENFACT(R) [coagulation factor VIIa (recombinant)-jncw] for Treatment and Control of Bleeding Episodes Occurring in Adult and Adolescent Hemophilia A and B Patients with Inhibitors
Biopharmaceuticals FDA
 HSMN NewsFeed - 23 Dec 2019
European Medicines Agency Validates BioMarin's Marketing Authorization Application for Valoctocogene Roxaparvovec to Treat Severe Hemophilia A
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 28 May 2019
BioMarin Announces that Phase 3 Cohort of Valoctocogene Roxaparvovec, Gene Therapy Study in Severe Hemophilia A Met Pre-Specified Criteria for Regulatory Submissions in the U.S. and Europe
Biopharmaceuticals
 HSMN NewsFeed - 17 Jan 2018
Pharming Announces FDA Acceptance for Review of Supplemental Biologics License Application for RUCONEST(R) for Prophylaxis of Hereditary Angioedema Attacks
Biopharmaceuticals FDA
 HSMN NewsFeed - 27 Nov 2017
Pharming Submits Supplemental Biologics License Application to FDA for RUCONEST(R) for Prophylaxis of Hereditary Angioedema Attacks
Biopharmaceuticals FDA
 HSMN NewsFeed - 16 Nov 2017
FDA Approves New Treatment to Prevent Bleeding in Certain Patients with Hemophilia A
Biopharmaceuticals FDA
 HSMN NewsFeed - 26 Oct 2017
FDA Grants Breakthrough Therapy Designation for BioMarin's Valoctocogene Roxaparvovec (formerly BMN 270), an Investigational Gene Therapy for Hemophilia A
Biopharmaceuticals FDA
 HSMN NewsFeed - 7 Jun 2017
Sangamo Therapeutics And Pfizer Announce That SB-525 Investigational Hemophilia A Gene Therapy Receives Orphan Medicinal Product Designation From The European Medicines Agency
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 18 May 2017
Swedish Orphan Biovitrum AB - Elocta(R) Approved in the Kingdom of Saudi Arabia for the Treatment of Haemophilia A
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 16 Jan 2017
European Commission Amends Marketing Authorisation for RUCONEST(R) to Include Self-Administration
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 27 Dec 2016
Shire Announces FDA Approval of Adynovate(R) for use in Children and Surgical Settings
Biopharmaceuticals FDA
 HSMN NewsFeed - 22 Dec 2016
Genentech’s Emicizumab for Hemophilia A Meets Primary Endpoint in Phase III Study
Biopharmaceuticals
 HSMN NewsFeed - 8 Dec 2016
Pharming Announces Completion of Acquisition of All North American Commercialisation Rights for RUCONEST(R) From Valeant
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 11 Nov 2016
CHMP Adopts Positive Opinion to Include Self-administration for RUCONEST(R)
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 1 Aug 2016
Shire Announces FDA Approval of adynovate with BAXJECT III Reconstitution System
Biopharmaceuticals FDA
 HSMN NewsFeed - 20 Jun 2016
Sangamo BioSciences Announces FDA Clearance of Investigational New Drug Application for ZFN-Mediated Genome Editing Treatment of MPS II
Biopharmaceuticals FDA
 HSMN NewsFeed - 7 Apr 2016
Pharming Announces Adoption by the European Commission of the CHMP Recommendation to Change the Terms of the Marketing Authorisation for Ruconest(R)
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 8 Feb 2016
Sangamo BioSciences Announces FDA Clearance Of Investigational New Drug Application For ZFN-Mediated Genome Editing Treatment Of MPS I
Biopharmaceuticals FDA
 HSMN NewsFeed - 1 Dec 2015
Sangamo BioSciences Announces FDA Clearance Of Investigational New Drug Application For SB-FIX, First In Vivo Protein Replacement Platform Program For Treatment Of Hemophilia B
Biopharmaceuticals FDA
 HSMN NewsFeed - 24 Nov 2015
Sobi and Biogen’s ELOCTA(R) (rFVIIIFc) Approved in Europe for the Treatment of Haemophilia A
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 15 Sep 2015
FDA Approves Octapharma’s NUWIQ for the Treatment of Adults and Children with Hemophilia
Biopharmaceuticals FDA
 HSMN NewsFeed - 8 Sep 2015
Selecta Announces $38 Million Series E Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 4 Sep 2015
U.S. FDA Grants Breakthrough Therapy Designation for Genentech’s Investigational Medicine ACE910 for People With Hemophilia A With Factor VIII Inhibitors
Biopharmaceuticals FDA
 HSMN NewsFeed - 28 Jul 2015
U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A
Biopharmaceuticals FDA
 HSMN NewsFeed - 20 Jul 2015
BioMarin Provides Program Update for Talazoparib in Metastatic Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Oct 2014
Selecta Announces More than $20 Million in Equity Funding
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 26 Aug 2014
Health Canada Approves Eloctate(TM), the First Therapy to Extend the Interval Between Prophylactic Infusions in Hemophilia A
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 23 Jun 2014
Bayer HealthCare and Dimension Therapeutics to Develop Novel Gene Therapy for Hemophilia A
Biopharmaceuticals
 HSMN NewsFeed - 18 Feb 2014
Bayer's Long-Acting Recombinant Factor VIII Demonstrated Prophylaxis with Less Frequent Infusions in Hemophilia A in Phase III Trial
Biopharmaceuticals
 HSMN NewsFeed - 13 Jan 2014
BioMarin Announces Selection of Factor VIII Gene Therapy Drug Development Candidate BMN 270 for the Treatment of Hemophilia A
Biopharmaceuticals
 HSMN NewsFeed - 19 Dec 2013
Baxter Receives FDA Approval of FEIBA [Anti-Inhibitor Coagulant Complex] for Prophylactic Treatment of Hemophilia A&B Patients with Inhibitors
Biopharmaceuticals FDA
 HSMN NewsFeed - 8 Jul 2013
Bayer Initiates Phase III Trial of an Investigational Recombinant Factor VIII Compound in Children with Hemophilia A
Biopharmaceuticals
 HSMN NewsFeed - 24 Jan 2013
Baxter Announces Agreement to Acquire Investigational Hemophilia Compound OBI-1 and Related Assets
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 28 Nov 2012
Bayer Announces Recruitment Achievement for Investigational Hemophilia Treatment
Biopharmaceuticals
 HSMN NewsFeed - 20 Nov 2012
Ipsen and Inspiration Biopharmaceuticals Announce That OBI-1 Has Received Fast Track Designation from FDA for Acquired Hemophilia A
Biopharmaceuticals
 HSMN NewsFeed - 31 Oct 2012
Inspiration Biopharmaceuticals Files for Chapter 11 Protection in Order to Pursue a Broad Strategic Transaction
Biopharmaceuticals
 HSMN NewsFeed - 18 Sep 2012
Biopharmaceutical Industry Veterans Join Inspiration Biopharmaceuticals Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 21 Aug 2012
Inspiration Biopharmaceuticals Announces New Global Commercialization Agreements with Ipsen
Biopharmaceuticals Licensing
 HSMN NewsFeed - 2 Aug 2012
Inspiration Biopharmaceuticals Expands Industry Expertise with Five New Executive Hires
Biopharmaceuticals Personnel
 HSMN NewsFeed - 17 Apr 2012
ThromboGenics Resubmits BLA for Ocriplasmin With the FDA
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 17 Apr 2012
Inspiration Biopharmaceuticals Announces Filing of Biologics License Application (BLA) for IB1001, a Recombinant Factor IX Product for People with Hemophilia B
Biopharmaceuticals
 HSMN NewsFeed - 16 Mar 2012
ThromboGenics Enters Into Commercialization Agreement for Ocriplasmin With Alcon Outside the United States
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 11 Oct 2011
Inspiration Biopharmaceuticals Names John P. Butler Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 Dec 2010
Swedish Orphan Biovitrum's Long-Lasting Hemophilia A Therapy Receives Orphan Drug Designation in the US
Biopharmaceuticals FDA
 HSMN NewsFeed - 1 Sep 2010
Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 9 Aug 2010
Pfizer Receives FDA Approval for Prefilled Dual-Chamber Syringe for Use in the Treatment of Hemophilia A
Biopharmaceuticals Drug Delivery FDA
 HSMN NewsFeed - 19 Jul 2010
Phage Pharmaceuticals Appoints David Jackson as Vice President, Operations Planning
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 Jun 2010
Bayer HealthCare Introduces First Mobile Application to Assist Hemophilia A Patients in Managing Their Treatment
Biopharmaceuticals
 HSMN NewsFeed - 13 Jan 2010
Octapharma Receives Orphan Drug Exclusivity Approval for wilate(R) - A Replacement Therapy Developed Specifically for von Willebrand Disease
Biopharmaceuticals FDA
 HSMN NewsFeed - 7 Dec 2009
Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease
Biopharmaceuticals FDA
 HSMN NewsFeed - 13 Oct 2009
Transdel Pharmaceuticals Appoints Dr. Joachim P.H. Schupp as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 30 Jun 2009
Wyeth Pharmaceuticals and Catalyst Biosciences Announce Agreement to Develop and Commercialize Factor VIIa Products
Biopharmaceuticals
 HSMN NewsFeed - 11 Mar 2009
European Commission Approves ReFacto AF(TM) as a Variation to the Refacto(R) Marketing Authorisation
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 24 Nov 2008
Biovitrum's and Syntonix's Novel Factor IXFc for Hemophilia B has Received Orphan Drug Designation From the FDA
Biopharmaceuticals FDA
 HSMN NewsFeed - 10 Oct 2008
FDA Approves Bayer HealthCare's Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A
Biopharmaceuticals FDA
 HSMN NewsFeed - 8 Sep 2008
New Recombinant XYNTHA Now Available for Patients with Hemophilia A
Biopharmaceuticals
 HSMN NewsFeed - 28 Aug 2008
ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 Jul 2008
Bayer HealthCare and Maxygen Announce Hematology Agreement
Biopharmaceuticals Licensing Acquisitions
 HSMN NewsFeed - 13 May 2008
FDA Approves NOVO NORDISK's NovoSeven(R) RT (Coagulation Factor VIIa [Recombinant] Room Temperature Stable) for Hemophilia Patients With Inhibitors
Biopharmaceuticals FDA
 HSMN NewsFeed - 9 Apr 2008
Abraxis BioScience Announces Approval to Market ABRAXANE for Metastatic Breast Cancer in Korea
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 21 Feb 2008
Wyeth's XYNTHA Approved by FDA for Treatment of Hemophilia A
Biopharmaceuticals FDA
 HSMN NewsFeed - 28 Jan 2008
BioMarin Appoints Dr. Gordon Vehar, Vice President of Research
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 Jan 2008
LFB Biotechnologies to Collaborate with GTC Biotherapeutics on Coagulation Factor IX Program
Biopharmaceuticals
 HSMN NewsFeed - 7 Jan 2008
Baxter Announces Recombinant Factor IX Development Program For Hemophilia B
Biopharmaceuticals
 HSMN NewsFeed - 19 Dec 2007
CSL Behring Expands Into Middle East Market with Haemate(R) P
Biopharmaceuticals
 HSMN NewsFeed - 4 Dec 2007
ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 30 Jul 2007
ThermoGenesis Corp. Obtains FDA Clearance to Market CryoSeal(R) Fibrin Sealant (FS) in Liver Resection Surgeries
Devices FDA Surgery
 HSMN NewsFeed - 3 Jul 2007
Wyeth Begins Marketing and Distributing BeneFIX in Europe
Biopharmaceuticals Distribution
 HSMN NewsFeed - 29 Jun 2007
Bayer HealthCare Announces New 2000 IU Vial Size for Kogenate(R) FS Treatments
Biopharmaceuticals
 HSMN NewsFeed - 30 Apr 2007
Humate-P(R) Approved to Prevent Excessive Bleeding in Patients with von Willebrand Disease Undergoing Surgery
Biopharmaceuticals FDA
 HSMN NewsFeed - 4 Apr 2007
Bayer Healthcare Pharmaceuticals Officially Launches in the United States
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 26 Mar 2007
Wyeth Receives FDA Approval for New BeneFIX Features That Provide Hemophilia B Patients a Simpler and More Convenient Preparation Process for Recombinant Factor IX
Biopharmaceuticals FDA
 HSMN NewsFeed - 22 Mar 2007
Pain Therapeutics Licenses Biotechnology To Treat Rare Disorder
Biopharmaceuticals Licensing
 HSMN NewsFeed - 5 Feb 2007
Wyeth Pharmaceuticals and MediVas Announce Research Partnership to Develop Advanced Hemophilia Therapies
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 5 Feb 2007
Wyeth Pharmaceuticals and Nautilus Biotech Announce Collaboration to Develop Hemophilia Therapies
Biopharmaceuticals Licensing
 HSMN NewsFeed - 1 Feb 2007
CSL Behring and Bayer Extend Agreement for Supply of Helixate(R) Recombinant Coagulation Factor
Biopharmaceuticals Licensing Distribution
 HSMN NewsFeed - 1 Feb 2007
Grifols Announces FDA Approval of Alphanate(R) to Treat von Willebrand Disease
Biopharmaceuticals FDA
 HSMN NewsFeed - 4 Jan 2007
Biogen Idec to Acquire Syntonix
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 2 Jan 2007
Hospitals, Healthcare Providers to Save with Premier Plasma Distribution Agreement with FFF Enterprises
Biopharmaceuticals Group Purchasing
 HSMN NewsFeed - 15 Dec 2006
Lipoxen Announces $75M Agreement With Baxter to Develop New Blood Clotting Factors
Biopharmaceuticals Drug Delivery Licensing
 HSMN NewsFeed - 17 Oct 2006
NovoSeven(R) Becomes First and Only Recombinant Therapy for Treatment of Rare, Life-Threatening Bleeding Disorder
Biopharmaceuticals FDA
 HSMN NewsFeed - 11 Oct 2006
Baxter Announces Launch of BAXJECT(R) II Needle-Less Transfer Device for ADVATE(R)
Devices
 HSMN NewsFeed - 17 Jul 2006
Bayer HealthCare Introduces Free Product Trial Program For Kogenate(R) FS with BIO-SET(R)
Biopharmaceuticals
 HSMN NewsFeed - 18 May 2006
Baxter and Jerini Advance Program to Develop Non-Intravenous Hemophilia Therapy
Biopharmaceuticals
 HSMN NewsFeed - 9 May 2006
Baxter Receives FDA Approval for Ultra-High Dosage Strength of ADVATE for Hemophilia A
Biopharmaceuticals FDA
Return to NewsFeed  

 Additional items found! 37

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 37 additional stories matching:
factor VIII
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.